Carnegie Mellon’s Joel McManus and Pitt’s Robert Nicholls received a $162,000 grant from the Foundation for Prader-Willi Research to study the regulation and function of a key gene that is usually ...

New Epidemiological Insights into Mydriasis Reveal Projected Increase in Eye Exams and Surgeries Through 2034Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Prader-Willi Syndrome - Epidemiology ...

The new Prescription Drug User Fee Act (PDUFA) date for diazoxide choline extended-release (DCCR) is slated for 27 March 2025 ...

A recent epidemiology forecast provides an extensive review of Prader-Willi Syndrome (PWS), projecting the evolution of the disease through 2034. This report intends to furnish healthcare ...

According to Soleno Therapeutics, the FDA required more time to review responses to recent information requests. The FDA has extended the review period for the NDA for DCCR tablets for the treatment ...

DelveInsight’s "Prader–Willi Syndrome Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of PWS, historical and forecasted epidemiology as ...

PDUFA target action date extended by three months to March 27, 2025REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- , ...

for the treatment of adults and children aged 4 years and older with Prader-Willi syndrome (PWS) who have hyperphagia. The investigational product is an extended-release formulation of diazoxide ...

(SLNO) Tuesday announced that the FDA has extended the review period for the New Drug Application for DCCR tablets targeted at patients with Prader-Willi syndrome. DCCR is a proprietary extended ...

The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening condition ...